691 related articles for article (PubMed ID: 22925929)
1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
2. T cell-intrinsic factors contribute to the differential ability of CD8+ T cells to rapidly secrete IFN-γ in the absence of antigen.
Bou Ghanem EN; Nelson CC; D'Orazio SE
J Immunol; 2011 Feb; 186(3):1703-12. PubMed ID: 21191063
[TBL] [Abstract][Full Text] [Related]
3. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag.
Cottalorda A; Mercier BC; Mbitikon-Kobo FM; Arpin C; Teoh DY; McMichael A; Marvel J; Bonnefoy-Bérard N
Eur J Immunol; 2009 Oct; 39(10):2673-81. PubMed ID: 19634192
[TBL] [Abstract][Full Text] [Related]
4. Signal 3 requirement for memory CD8+ T-cell activation is determined by the infectious pathogen.
Keppler SJ; Aichele P
Eur J Immunol; 2011 Nov; 41(11):3176-86. PubMed ID: 21830209
[TBL] [Abstract][Full Text] [Related]
5. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.
Kezuka T; Streilein JW
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1803-11. PubMed ID: 10845601
[TBL] [Abstract][Full Text] [Related]
6. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
8. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
9. Type I IFN substitutes for T cell help during viral infections.
Wiesel M; Kratky W; Oxenius A
J Immunol; 2011 Jan; 186(2):754-63. PubMed ID: 21160039
[TBL] [Abstract][Full Text] [Related]
10. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo.
Schluns KS; Kieper WC; Jameson SC; Lefrançois L
Nat Immunol; 2000 Nov; 1(5):426-32. PubMed ID: 11062503
[TBL] [Abstract][Full Text] [Related]
13. Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
Hunter MR; Prosser ME; Mahadev V; Wang X; Aguilar B; Brown CE; Forman SJ; Jensen MC
Mol Immunol; 2013 Nov; 56(1-2):1-11. PubMed ID: 23628622
[TBL] [Abstract][Full Text] [Related]
14. IL-15 is critical for the maintenance and innate functions of self-specific CD8(+) T cells.
Itsumi M; Yoshikai Y; Yamada H
Eur J Immunol; 2009 Jul; 39(7):1784-93. PubMed ID: 19544306
[TBL] [Abstract][Full Text] [Related]
15. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo.
Schmidt CS; Mescher MF
J Immunol; 1999 Sep; 163(5):2561-7. PubMed ID: 10452994
[TBL] [Abstract][Full Text] [Related]
17. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
18. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections.
Bachmann MF; Wolint P; Walton S; Schwarz K; Oxenius A
Eur J Immunol; 2007 Jun; 37(6):1502-12. PubMed ID: 17492805
[TBL] [Abstract][Full Text] [Related]
19. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]